Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2814 with Lecanemab in Early Alzheimer's Disease
NCT06602258Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of etalanetug in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoint: Change From Baseline in CSF MTBR-tau-243 at 6 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
etalanetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06602258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602258.